BioArctic: Gunilla Osswald awarded Uppsala University Alumnus of the year 2025
Rhea-AI Summary
BioArctic (NASDAQ STOCKHOLM: BIOA B) announced that CEO Gunilla Osswald has been named Uppsala University's Alumnus of the Year 2025. The recognition highlights her exemplary leadership and contributions to scientific innovation, particularly in the development of lecanemab for Alzheimer's disease.
Earlier in March 2025, Osswald and BioArctic's founders were also awarded the university's Innovation and Entrepreneurship Prize. The university praised her visionary and inclusive leadership style, noting her ability to foster collaboration and serve as a role model for women in science and technology.
Positive
- None.
Negative
- None.
News Market Reaction – BIOA
On the day this news was published, BIOA declined 2.16%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
The motivation reads: As a business leader, she is visionary and inclusive. She creates a shared sense of purpose, a strong feeling of meaning, and a culture characterized by collaboration-both within the organization and in dialogue with external partners. Gunilla Osswald is an inspiring role model for students and researchers, especially women in science and technology. Her work demonstrates that it is possible to unite scientific integrity with leadership, entrepreneurship, and global impact.
Gunilla Osswald trained as a pharmacist and earned a PhD at Uppsala University. Since 2014, she has served as CEO of BioArctic. Earlier this year, on March 12, 2025, Gunilla Osswald, together with BioArctic's two founders, Lars Lannfelt and Pär Gellerfors, was awarded Uppsala University's Innovation and Entrepreneurship Prize for successfully addressing a growing global health problem through their work in developing the drug lecanemab, which slows the progression of Alzheimer's disease.
"Universities play a vital role in development and innovation. I am deeply honored by this award. Uppsala University has had a profound influence on who I have become as well as on the successes our company has achieved. My driving force has always been to help patients, and through my studies at the Faculty of Pharmacy, I laid the foundation for this important work," says Gunilla Osswald, CEO of BioArctic and Uppsala University's Alumnus of the Year 2025.
The information was released for public disclosure, through the agency of the contact person below, on September 9, 2025, at 09:00 CET.
For further information, please contact:
Oskar Bosson, VP Communications and IR
E-mail: oskar.bosson@bioarctic.com
Phone: +46 70 410 71 80
Images of Gunilla Osswald can be found on the company website:
https://www.bioarctic.com/en/media/image-bank/
Motivation
As a business leader, she is visionary and inclusive. She creates a shared sense of purpose, a strong feeling of meaning, and a culture characterized by collaboration-both within the organization and in dialogue with external partners. Gunilla Osswald is an inspiring role model for students and researchers, especially women in science and technology. Her work demonstrates that it is possible to unite scientific integrity with leadership, entrepreneurship, and global impact.
About the Uppsala University Alumnus of the Year Award
Each year, Uppsala University presents the Alumnus of the Year award to someone who has made outstanding contributions in their career or has otherwise distinguished themselves through work that the university deems worthy of recognition. https://www.uu.se/en/about-uu/academic-traditions/traditions/alumnus-of-the-year
About BioArctic AB
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) - the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic's partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.com.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Gunilla Osswald awarded Uppsala University Alumnus of the year 2025 | |
https://news.cision.com/bioarctic/i/gunilla-osswald,c3467996 | Gunilla Osswald |
View original content:https://www.prnewswire.com/news-releases/bioarctic-gunilla-osswald-awarded-uppsala-university-alumnus-of-the-year-2025-302550423.html
SOURCE BioArctic
FAQ
Who is Gunilla Osswald and what award did she receive in 2025?
What achievements led to Gunilla Osswald's recognition at Uppsala University?
What other award did BioArctic's CEO receive from Uppsala University in 2025?
What is Gunilla Osswald's educational background?
